How do patent-based measures inform product commercialization? —The case of the United States pharmaceutical industry
Authors:
- Hsin-Ning SuHSHsin-Ning Su
- Yi-Siang LinYLYi-Siang Lin
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Journal of Engineering and Technology Management
- Vol. 50, 24-38
Abstract
No abstract availableKeywords
Funding Information
- Ministerio de Ciencia y Tecnología
- Ministry of Science and Technology, Taiwan (106-2410-H-005-040-MY2)
This publication has 99 references indexed in Scilit:
- Knowledge sources, patent protection, and commercialization of pharmaceutical innovationsResearch Policy, 2010
- The size distribution of innovations revisited: An application of extreme value statistics to citation and value measures of patent significanceJournal of Econometrics, 2007
- New product development process and time-to-market in the generic pharmaceutical industryIndustrial Marketing Management, 2006
- Estimating The Cost Of New Drug Development: Is It Really $802 Million?Health Affairs, 2006
- Key factors in the rising cost of new drug discovery and developmentNature Reviews Drug Discovery, 2004
- The Value of Improving the Productivity of the Drug Development ProcessPharmacoEconomics, 2002
- Technological Convergence in the IT Industry: The Role of Strategic Technology Alliances and Technological CompetenciesInternational Journal of the Economics of Business, 1998
- University Versus Corporate Patents: A Window On The Basicness Of InventionEconomics of Innovation and New Technology, 1997
- The strategic management of R&D collaborationTechnology Analysis & Strategic Management, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958